Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020

Rhea-AI Summary

Flexion Therapeutics (Nasdaq: FLXN) announced its plans to report second-quarter 2020 financial results on August 5, 2020, after U.S. market close. The company focuses on developing innovative, local therapies aimed at treating musculoskeletal conditions, particularly osteoarthritis. This upcoming financial report may provide insights into the company's performance and future outlook.

Positive

• Focus on developing innovative therapies for musculoskeletal conditions.

Negative

• None.

BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com.

Contact:

Scott Young
Vice President, Corporate Communications & Investor Relations
T: 781-305-7194
syoung@flexiontherapeutics.com

FAQ

When will Flexion Therapeutics report its second-quarter 2020 financial results?

Flexion Therapeutics will report its second-quarter 2020 financial results on August 5, 2020, after the U.S. market closes.

What is the stock symbol for Flexion Therapeutics?

The stock symbol for Flexion Therapeutics is FLXN.

What conditions does Flexion Therapeutics focus on?

Flexion Therapeutics focuses on developing treatments for musculoskeletal conditions, beginning with osteoarthritis.